Universität zu Köln

Journal Article

Kaddu-Mulindwa, Dominic, Altmann, Bettina, Robrecht, Sandra, Ziepert, Morita, Regitz, Evi, Tausch, Eugen, Held, Gerhard, Poeschel, Viola, Lesan, Vadim, Bittenbring, Joerg Thomas ORCID: 0000-0003-3864-8315, Thurner, Lorenz, Pfreundschuht, Michael, Christofyllakis, Konstantinos ORCID: 0000-0002-0308-388X, Truemper, Lorenz, Loeffler, Markus, Schmitz, Norbert, Hoth, Markus ORCID: 0000-0001-7080-4643, Hallek, Michael ORCID: 0000-0002-7425-4455, Fischer, Kirsten, Stilgenbauer, Stephan, Bewarder, Moritz and Rixecker, Torben Millard (2022). KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Lancet Haematol., 9 (2). S. E133 - 10. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Pfreundschuh, Michael, Christofyllakis, Konstantinos, Altmann, Bettina, Ziepert, Marita, Haenel, Mathias, Viardot, Andreas, Neubauer, Andreas, Held, Gerhard, Truemper, Lorenz, Schmidt, Christian, Kanz, Lothar, Hallek, Michael J., Schmitz, Norbert, Heintges, Tobias, Koelbel, Christian, Schneider, Guenther, Ruebe, Christian, Hellwig, Dirk ORCID: 0000-0002-3056-0143, Poeschel, Viola and Murawski, Niels (2017). Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL > 60 study of the DSHNHL. J. Clin. Oncol., 35. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Altmann, Bettina, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Viardot, Andreas, Borchmann, Peter, Kanz, Lothar, Keller, Ulrich, Schmidt, Christian, Mahlberg, Rolf, Metzner, Bernd, Marks, Reinhard, Hoeffkes, Heinz-Gert, Christofyllakis, Konstantinos, Amam, Josif, Berdel, Christian, Stilgenbauer, Stephan, Schmitz, Norbert, Truemper, Lorenz, Murawski, Niels, Loeffler, Markus and Pfreundschuh, Michael (2018). Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Witzens-Harig, Mathias, Holte, Harald, Thurner, Lorenz, Borchmann, Peter, Viardot, Andreas, Soekler, Martin, Keller, Ulrich, Schmidt, Christian, Truemper, Lorenz, Mahlberg, Rolf, Marks, Reinhard, Hoeffkes, Heinz-Gert, Metzner, Bernd, Dierlamm, Judith, Frickhofen, Norbert, Haenel, Mathias, Neubauer, Andreas, Kneba, Michael, Merli, Francesco, Tucci, Alessandra ORCID: 0000-0003-3052-7463, Brown, Peter de Nully ORCID: 0000-0002-6522-4086, Federico, Massimo, Lengfelder, Eva, di Rocco, Alice, Trappe, Ralf ORCID: 0000-0001-7565-7160, Rosenwald, Andreas, Berdel, Christian, Maisenhoelder, Martin, Shpilberg, Ofer, Amam, Josif, Christofyllakis, Konstantinos ORCID: 0000-0002-0308-388X, Hartmann, Frank, Murawski, Niels, Stilgenbauer, Stephan, Nickelsen, Maike, Wulf, Gerald, Glass, Bertram, Schmitz, Norbert, Altmann, Bettina, Loeffler, Markus and Pfreundschuh, Michael (2019). Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet, 394 (10216). S. 2271 - 2282. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-547X